GSK3B and Alzheimer disease: Treatment with low-dose THC at 0.2 and 0.02 mg/kg improved the spatial learning of aged APP/PS1 mice by reducing the expression levels of oligomeric Aβ, phospho-tau and total tau and decreasing the activity of GSK-3β without eliciting any psychotropic or immunomodulatory effects, suggesting that low-dose THC is a safe and effective treatment for AD.